Search Results - "Mahaffey, K. W."

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: Results from ROCKET AF by Girgis, I.G., Patel, M.R., Peters, G.R., Moore, K.T., Mahaffey, K.W., Nessel, C.C., Halperin, J.L., Califf, R.M., Fox, K.A.A., Becker, R.C.

“…Two once‐daily rivaroxaban dosing regimens were compared with warfarin for stroke prevention in patients with non‐valvular atrial fibrillation in ROCKET AF: 20…”
Get full text

Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction : Results of a multicenter, randomized, placebo-controlled trial : The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial by MAHAFFEY, K. W, PUMA, J. A, ORLANDI, C, BLEVINS, R, GIBBONS, R. J, CALIFF, R. M, GRANGER, C. B, BARBAGELATA, N. A, DICARLI, M. F, LEESAR, M. A, BROWNE, K. F, EISENBERG, P. R, BOLLI, R, CASAS, A. C, MOLINA-VIAMONTE, V

“…The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial was designed to test the hypothesis that adenosine as an adjunct to thrombolysis would…”
Get full text

Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes by Roe, M.T., Mahaffey, K.W., Kilaru, R., Alexander, J.H., Akkerhuis, K.M., Simoons, M.L., Harrington, R.A., Tardiff, B.E., Granger, C.B., Ohman, E.M., Moliterno, D.J., Lincoff, A.M., Armstrong, P.W., Van de Werf, F., Califf, R.M., Topol, E.J.

“…Aim To study the relationship between outcomes and peak creatine kinase (CK)-MB levels after percutaneous coronary intervention (PCI) in patients with…”
Get full text

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes by Fulcher, G., Matthews, D. R., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., Shaw, W., Vercruysse, F., Meininger, G., Neal, B.

“…Aims To assess the efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes enrolled in the…”
Get full text

Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial by GEBEL, J. M, SILA, C. A, SLOAN, M. A, GRANGER, C. B, WEISENBERGER, J. P, GREEN, C. L, TOPOL, E. J, MAHAFFEY, K. W

“…The volume of an intracerebral hemorrhage has been shown to be an important independent predictor of mortality in several reports. A technique for estimating…”
Get full text

Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT by Akkerhuis, K.M, Deckers, J.W, Boersma, E, Harrington, R.A, Stepinska, J, Mahaffey, K.W, Wilcox, R.G, Lincoff, A.M, Keltai, M, Topol, E.J, Califf, R.M, Simoons, M.L

“…Aims Variations in outcome of patients from different geographic regions have been observed in many large international trials. We analysed the factors that…”
Get full text

Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation by Lopes, R D, Pieper, K S, Horton, J R, Al-Khatib, S M, Newby, L K, Mehta, R H, Van de Werf, F, Armstrong, P W, Mahaffey, K W, Harrington, R A, Ohman, E M, White, H D, Wallentin, L, Granger, C B

“…To assess variables associated with the occurrence of atrial fibrillation (AF) and the relation of AF with short- and long-term outcomes and with other…”
Get more information

Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? by Hersi, A., Fu, Y., Wong, B., Mahaffey, K.W., Harrington, R.A., Califf, R.M., Van de Werf, F., Armstrong, P.W.

“…Background Although the prognostic value of admission ST changes in patients with non-ST elevation acute coronary syndrome (ACS) is established, the utility of…”
Get full text

Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes by MARK, D. B, HARRINGTON, R. A, LINCOFF, A. M, CALIFF, R. M, NELSON, C. L, TSIATIS, A. A, BUELL, H, MAHAFFEY, K. W, DAVIDSON-RAY, L, TOPOL, E. J

“…In the PURSUIT trial, eptifibatide significantly reduced the 30-day incidence of death and myocardial infarction relative to placebo in 9461 patients with an…”
Get full text

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial by Chang, T I, Abdalla, S, London, G M, Block, G A, Correa-Rotter, R, Drüeke, T B, Floege, J, Herzog, C A, Mahaffey, K W, Moe, S M, Parfrey, P S, Wheeler, D C, Dehmel, B, Goodman, W G, Chertow, G M

“…Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which…”
Get full text

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial by GRANGER, Christopher B, MAHAFFEY, Kenneth W, ARMSTRONG, Paul W, WEAVER, W. Douglas, THEROUX, Pierre, HOCHMAN, Judith S, FILLOON, Thomas G, ROLLINS, Scott, TODARO, Thomas G, NICOLAU, Jose C, RUZYLLO, Witold

“…Complement, activated during myocardial ischemia and reperfusion, causes myocardial damage through multiple processes. The COMplement inhibition in Myocardial…”
Get full text

Left ventricular performance and remodeling in rabbits after myocardial infarction : effects of a thyroid hormone analogue by MAHAFFEY, K. W, RAYA, T. E, PENNOCK, G. D, MORKIN, E, GOLDMAN, S

“…Because the rat postinfarction model differs from human heart failure with respect to the composition of myosin heavy chain (MHC) isoforms and other…”
Get full text

Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial by Galani, Jemi, Mulder, Hillary, Rockhold, Frank W, Weissler, E Hope, Baumgartner, Iris, Berger, Jeffrey S, Blomster, Juuso I, Fowkes, F Gerry R, Hiatt, William R, Katona, Brian G, Norgren, Lars, Mahaffey, Kenneth W, Quint, Jennifer K, Patel, Manesh R, Jones, W Schuyler

“…Patients with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lower extremity peripheral artery disease (PAD) and suffering…”
Get full text

Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis results from GUSTO-I by MAHAFFEY, K. W, GRANGER, C. B, CALIFF, R. M, SLOAN, M. A, THOMPSON, T. D, GORE, J. M, WEAVER, W. D, WHITE, H. D, SIMOONS, M. L, BARBASH, G. I, TOPOL, E. J

“…Nonhemorrhagic stroke occurs in 0.1% to 1.3% of patients with acute myocardial infarction who are treated with thrombolysis, with substantial associated…”
Get full text

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction : Review of ocular hemorrhage incidence and location in the GUSTO-I trial by MAHAFFEY, K. W, GRANGER, C. B, TOTH, C. A, WHITE, H. D, STEBBINS, A. L, BARBASH, G. I, VAHANIAN, A, TOPOL, E. J, CALIFF, R. M

Get full text

Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Experience from the GUSTO-I Trial by Mahaffey, Kenneth W., Granger, Christopher B., Sloan, Michael A., Green, Cindy L., Gore, Joel M., Weaver, W.Douglas, White, Harvey D., Simoons, Maarten L., Barbash, Gabriel I., Topol, Eric J., Califf, Robert M.

“…Background Intracranial hemorrhage is an uncommon but very dangerous complication in patients receiving thrombolytic therapy for acute myocardial infarction…”
Get full text

Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial by MAHAFFEY, Kenneth W, GRANGER, Christopher B, ARMSTRONG, Paul W, NICOLAU, Jose C, RUZYLLO, Witold, WEAVER, W. Douglas, THEROUX, Pierre, HOCHMAN, Judith S, FILLOON, Thomas G, MOJCIK, Christopher F, TODARO, Thomas G

“…Complement activation mediates myocardial damage that occurs during ischemia and reperfusion through multiple pathways. We performed 2 separate, parallel,…”
Get full text

Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage by SLOAN, M. A, SILA, C. A, GREEN, C. L, TOPOL, E. J, CALIFF, R. M, MAHAFFEY, K. W, GRANGER, C. B, LONGSTRETH, W. T, KOUDSTAAL, P, WHITE, H. D, GORE, J. M, SIMOONS, M. L, WEAVER, W. D

“…Limited information exists on risk factors for mortality after thrombolysis-related intracranial hemorrhage. We wished to determine the characteristics…”
Get full text

Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion by Roe, Matthew T, Ohman, E.Magnus, Maas, Arthur C.P, Christenson, Robert H, Mahaffey, Kenneth W, Granger, Christopher B, Harrington, Robert A, Califf, Robert M, Krucoff, Mitchell W

“…Successful reperfusion after acute myocardial infarction (MI) has traditionally been considered to be restoration of epicardial patency, but increasing…”
Get full text

Myonecrosis After Revascularization Procedures by Califf, Robert M., Abdelmeguid, Alaa E., Kuntz, Richard E., Popma, Jeffrey J., Davidson, Charles J., Cohen, Eric A., Kleiman, Neal S., Mahaffey, Kenneth W., Topol, Eric J., Pepine, Carl J., Lipicky, Ray J., Granger, Christopher B., Harrington, Robert A., Tardiff, Barbara E., Crenshaw, Brian S., Bauman, Robert P., Zuckerman, Bram D., Chaitman, Bernard R., Bittl, John A., Ohman, E.Magnus

“…The detection of elevated cardiac enzyme levels and the occurrence of electrocardiographic (ECG) abnormalities after revascularization procedures have been the…”
Get full text